EA201691112A1 - Образование антител ex vivo - Google Patents

Образование антител ex vivo

Info

Publication number
EA201691112A1
EA201691112A1 EA201691112A EA201691112A EA201691112A1 EA 201691112 A1 EA201691112 A1 EA 201691112A1 EA 201691112 A EA201691112 A EA 201691112A EA 201691112 A EA201691112 A EA 201691112A EA 201691112 A1 EA201691112 A1 EA 201691112A1
Authority
EA
Eurasian Patent Office
Prior art keywords
formation
vito
antibodies
vivo
methods
Prior art date
Application number
EA201691112A
Other languages
English (en)
Inventor
Хельден Паулина Мария Вильгельмина Ван
Марк Йерун Кваккенбос
Херген СПИТС
Тим Бомонт
Original Assignee
Аимм Терапьютикс Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аимм Терапьютикс Б.В. filed Critical Аимм Терапьютикс Б.В.
Publication of EA201691112A1 publication Critical patent/EA201691112A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae

Abstract

В настоящем изобретении предложены средства и способы для образования улучшенных В-клеточных культур ex vivo с коротким временем удвоения.
EA201691112A 2013-12-24 2014-12-24 Образование антител ex vivo EA201691112A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13199584 2013-12-24
PCT/NL2014/050908 WO2015099534A1 (en) 2013-12-24 2014-12-24 Ex vivo antibody production

Publications (1)

Publication Number Publication Date
EA201691112A1 true EA201691112A1 (ru) 2017-01-30

Family

ID=49885067

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691112A EA201691112A1 (ru) 2013-12-24 2014-12-24 Образование антител ex vivo

Country Status (15)

Country Link
US (2) US20170009205A1 (ru)
EP (2) EP3087177B1 (ru)
JP (1) JP6832705B2 (ru)
CN (1) CN106029873A (ru)
AU (1) AU2014370516B9 (ru)
BR (1) BR112016014881B1 (ru)
CA (1) CA2934660C (ru)
DK (1) DK3087177T3 (ru)
EA (1) EA201691112A1 (ru)
ES (1) ES2927905T3 (ru)
HU (1) HUE060145T2 (ru)
IL (1) IL246409B (ru)
MX (1) MX2016008345A (ru)
SG (1) SG11201605126YA (ru)
WO (1) WO2015099534A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6013356B2 (ja) * 2010-12-02 2016-10-25 アイム・セラピューティクス・べー・フェー 高親和性抗体を製造するための手段および方法
CN116554353B (zh) * 2023-04-28 2024-05-03 北京奇迈永华生物科技有限公司 一种假病毒高效感染人nk细胞及其他免疫细胞的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4343708B2 (ja) * 2002-04-26 2009-10-14 アンスティテュ ナシナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル−イ．エヌ．エス．ウ．エール．エム． 改良型キメラ糖タンパク質と、類型化されたレンチウイルス
WO2007019223A1 (en) * 2005-08-03 2007-02-15 Therapeutic Human Polyclonals, Inc. Suppression of b-cell apoptosis in transgenic animals expressing humanized immunoglobulin
PL2540820T3 (pl) * 2005-12-09 2018-05-30 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Środki i sposoby wpływania na stabilność komórek wytwarzających przeciwciała
EP2400298B1 (en) * 2010-05-28 2013-08-14 F.Hoffmann-La Roche Ag Single B-cell cultivation method and specific antibody production
JP6013356B2 (ja) * 2010-12-02 2016-10-25 アイム・セラピューティクス・べー・フェー 高親和性抗体を製造するための手段および方法
RU2017127486A (ru) * 2011-11-23 2019-02-06 Ф. Хоффманн-Ля Рош Аг Клетки млекопитающих, экспрессирующие лиганд cd40l, и их применение
WO2014109696A1 (en) * 2013-01-10 2014-07-17 Alf Grandien Method for immortalization of b cells and uses thereof
WO2015115892A1 (en) * 2014-01-31 2015-08-06 Aimm Therapeutics B.V. Means and methods for producing stable antibodies

Also Published As

Publication number Publication date
IL246409B (en) 2022-01-01
SG11201605126YA (en) 2016-07-28
NZ722156A (en) 2021-08-27
EP4141108A1 (en) 2023-03-01
US20170009205A1 (en) 2017-01-12
AU2014370516A1 (en) 2016-07-07
DK3087177T3 (da) 2022-10-03
MX2016008345A (es) 2017-02-08
ES2927905T3 (es) 2022-11-11
CN106029873A (zh) 2016-10-12
CA2934660A1 (en) 2015-07-02
EP3087177A1 (en) 2016-11-02
BR112016014881A8 (pt) 2020-06-09
HUE060145T2 (hu) 2023-02-28
AU2014370516B9 (en) 2021-07-29
AU2014370516B2 (en) 2021-03-11
CA2934660C (en) 2023-03-14
EP3087177B1 (en) 2022-09-14
BR112016014881B1 (pt) 2023-03-28
IL246409A0 (en) 2016-08-31
BR112016014881A2 (pt) 2017-08-08
US20200149007A1 (en) 2020-05-14
JP2017500052A (ja) 2017-01-05
JP6832705B2 (ja) 2021-02-24
WO2015099534A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
MX2020002289A (es) Anticuerpos anti-alfa-sinucleina y metodos de uso.
PH12016501143A1 (en) Anti-cd33 antibodies and immunoconjugates
PH12015502565B1 (en) Anti-transferrin receptor antibodies and methods of use
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
MX2020010141A (es) Anticuerpos anti-factor del complemento c1q y uso de los mismos.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX2013011479A (es) Anticuerpos anti-fgfr4 y metodos de uso.
PE20210648A1 (es) Anticuerpos anti-cd3 y metodos de uso
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
MY178142A (en) Anti-phf-tau antibodies and their uses
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
UY34456A (es) Anticuerpos anti-il-36r
UY34815A (es) Anticuerpos biespecíficos y sus métodos de uso
EA201400875A1 (ru) Антитела к cd47 и способы их применения
MX2014004022A (es) Anticuerpos anti-htra1 y metodos de uso.
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
UY34271A (es) Anticuerpos anti-tie2 y usos de los mismos
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
MX354303B (es) Anticuerpos de anti-biotina y metodos de uso.
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.